All references in this report to ZyVersa, the Company, we, us, or our mean ZyVersa Therapeutics, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Company Overview We are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients quality of life. We hav...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014271 | EDGAR | 55K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000862 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001493152-24-011073 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010259 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001213900-22-019895 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001493152-25-024263 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023342 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009724 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045351 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001493152-24-031002 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019517 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041185 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029603 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016480 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072377 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001213900-22-048196 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026061 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-16 | 0001493152-26-033565 | EDGAR | — |
| 2026-03-05 | 0001493152-26-008994 | EDGAR | 16K words |
| 2025-12-03 | 0001493152-25-025966 | EDGAR | — |
| 2025-11-19 | 0001493152-25-024273 | EDGAR | — |
| 2025-10-15 | 0001493152-25-018156 | EDGAR | — |
| 2025-09-18 | 0001493152-25-013968 | EDGAR | — |
| 2025-07-28 | 0001641172-25-021100 | EDGAR | — |
| 2025-07-16 | 0001641172-25-019856 | EDGAR | — |
| 2025-07-09 | 0001641172-25-018403 | EDGAR | — |
| 2025-06-25 | 0001641172-25-016388 | EDGAR | — |
106 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001859007 |
| Ticker | ZVSA |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ZVSA (~200 tokens, structured JSON with cryptographic provenance)